TransCode Therapeutics Appoints Scientific Advisory Board Chair and Signs Research Agreement with Michigan State University

TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical-stage company focused on RNA-based therapies for cancer, has appointed Anna Moore, PhD, as Chair of its Scientific Advisory Board and entered into a sponsored research agreement with Michigan State University. The developments are aimed at advancing the company's pipeline, including its lead candidate TTX-MC138, which targets metastatic tumors overexpressing microRNA-10b.

The appointment of Dr. Moore, a recognized expert in molecular imaging and nanomedicine, is expected to provide strategic guidance on research and development efforts. Dr. Moore currently serves as a professor at Michigan State University and has a background in developing imaging agents and therapeutics for cancer. Her leadership is anticipated to bolster TransCode's scientific direction as the company progresses its clinical programs.

The sponsored research agreement with Michigan State University will support the continued development of TTX-MC138, including evaluation of the candidate in combination with other therapies. This collaboration aligns with TransCode's mission to address high-risk and advanced cancers through innovative RNA-based approaches. The company's lead candidate targets microRNA-10b, a biomarker associated with metastasis, offering a potential treatment for aggressive tumors.

TransCode Therapeutics is a clinical-stage company pioneering immuno-oncology and RNA therapeutics. Its portfolio includes first-in-class candidates designed to mobilize the immune system against cancer cells. The company's focus on RNA-based treatments represents a growing area of interest in oncology, with potential to improve outcomes for patients with limited options.

For more information on TransCode Therapeutics, visit the company's newsroom at https://ibn.fm/RNAZ. The full press release can be accessed at https://ibn.fm/NA2NH.